Analysts at Deutsche Bank (DB) are out with a report this morning reiterating shares of BioMarin Pharmaceutical Inc. (BMRN) with a ‘Buy‘. The firm raised also its price target for the company to $140 from $90, implying 55% upside.
BioMarin Pharmaceutical Inc. shares have a t-12 price-to-sales ratio of 24.48. EPS for the same period is ($0.92).
In the past 52 weeks, shares of San Rafael California-based company have traded between a low of $55.04 and a high of $133.54 and are now at $129.68. Shares are up 65.10% year-over-year ; up 27.82% year-to-date.
Facebook, Inc. (FB) was reiterated as ‘Overweight’ with a $98 from $88 price target on Friday by Barclays.
On valuation measures, Facebook, Inc. shares are currently priced at 74.87x this year’s forecasted earnings compared to the industry’s 35.53x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.37 and 32.45, respectively. Price/Sales for the same period is 18.64 while EPS is $1.11. Currently there are 40 analysts that rate FB a ‘Buy’, 6 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. FB has a median Wall Street price target of $91.50 with a high target of $107.00.
In the past 52 weeks, shares of Menlo Park, California-based social networking company have traded between a low of $54.66 and a high of $86.07 and are now at $83.25. Shares are up 37.46% year-over-year and 6.40% year-to-date.
Analysts at Rosenblatt initiated coverage on ChinaCache International Holdings Ltd. (CCIH) with a ‘Buy’ rating in a research report issued to clients on Friday.
ChinaCache shares recently gained $1.28 to $10.00. In the past 52 weeks, shares of Beijing, China-based company have traded between a low of $7.91 and a high of $23.50. Shares are down 58.38% year-over-year and 5.11% year-to-date.
Novavax, Inc. (NVAX) coverage was resumed on Friday by Citigroup (C) with a ‘Buy’ rating and a 12-month case base estimate of $10.
NVAX shares recently $gained 0.63 to $8.21. The stock is up more than 72.27% year-over-year and has gained roughly 28% year-to-date. In the past 52 weeks, shares of Gaithersburg, Maryland-based clinical-stage vaccine firm have traded between a low of $3.34 and a high of $9.95.
Novavax, Inc.closed Thursday at $7.58. The name has a total market cap of $1.96 billion.
Amazon.com Inc. (AMZN) rating of ‘Buy’ was reiterated today at Citigroup (C) with a price target increase of $430 from $405 (versus a $367.35 previous close).
Amazon.com Inc., currently valued at $172.91 billion, has a median Wall Street price target of $400.00 with a high target of $475.00. Approximately 1.60 million shares have already changed hands, compared to the stock’s average daily volume of 3.76 million.
In the past 52 weeks, shares of the e-commerce giant have traded between a low of $284.00 and a high of $389.37 with the 50-day MA and 200-day MA located at $376.75 and $329.77 levels, respectively. Additionally, shares of AMZN trade at a P/E ratio of 34.17 and have a Relative Strength Index (RSI) and MACD indicator of 55.53 and -2.25, respectively.
AMZN currently prints a one year return of about 7% and a year-to-date return of around 18%.